Results 11 to 20 of about 924 (199)

Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii –Calcoaceticus Complex (ABC) Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

Canadian Journal of Infectious Diseases and Medical Microbiology
Summary: Sulbactam–durlobactam is a recently approved antimicrobial combination of two β-lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with ...
Wissam K Kabbara, Hanine Mansour
exaly   +3 more sources

Pharmacokinetic and pharmacodynamic evaluation of sulbactam-durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. [PDF]

Pharmacotherapy
Background: Drug databases currently do not provide dosing guidance for sulbactam-durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam-durlobactam during continuous ...
Kufel WD, Zeineddine N, Fouad A, Roenfanz HF, Shields RK, Kline EG, Warner J, Hanrahan K, Kuti JL.   +8 more
europepmc   +4 more sources

A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science, 2021
Durlobactam (formerly ETX2514) is a diazabicyclooctane β‐lactamase inhibitor that inhibits class A, C, and D β‐lactamases. Sulbactam combined with durlobactam has in vitro and in vivo activity against Acinetobacter baumannii including carbapenem‐ and ...
John O’Donnell, Kathleen Maloney, Melissa Steidler, Royce Morrison, Robin Isaacs   +4 more
doaj   +2 more sources

Bicyclic Boronate β-Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens [PDF]

Advanced Therapeutics, Volume 4, Issue 5, May 2021., 2021
The use of β-lactamase inhibitors in combination with β-lactam antibiotics is an emerging area in drug discovery. This strategy allows the restoration of the therapeutic efficacy of these antibiotics in clinical use against multiresistant bacteria. These
DeLano W. L., Dobozy O., Morrill H. J., Salahuddin P., Thayer A. M., Ventola C. L.   +5 more
core   +2 more sources

Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus

mBio, 2023
Mycobacterium abscessus (Mab) affects patients with immunosuppression or underlying structural lung diseases such as cystic fibrosis (CF). Additionally, Mab poses clinical challenges due to its resistance to multiple antibiotics.
Khalid M. Dousa, Eunjeong Shin, Sebastian G. Kurz, Mark Plummer, Mary Nantongo, Christopher R. Bethel, Magdalena A. Taracila, David C. Nguyen, Barry N. Kreiswith, Charles L. Daley, Kenneth E. Remy, Steven M. Holland, Robert A. Bonomo   +12 more
doaj   +4 more sources

New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam. [PDF]

Antimicrob Agents Chemother
ABSTRACT Infections due to Carbapenem-resistant Acinetobacter baumannii (CRAB) are a significant burden and are associated with devastating outcomes. Subsequently, CRAB is recognized as an urgent threat to human health by the United States (US) Centers for Disease Control ...
Pogue JM, Harrington J, Wangchinda W, Kaye KS.   +3 more
europepmc   +3 more sources

In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance [PDF]

Journal of Global Antimicrobial Resistance, 2022
: Objectives: Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health care settings as a frequent cause of serious infections with limited treatment ...
Jacqueline Findlay, Laurent Poirel, Maxime Bouvier, Patrice Nordmann   +3 more
doaj   +3 more sources

Failure of durlobactam to restore the susceptibility to meropenem in carbapenem-resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
Objective: Durlobactam, a diazabicyclooctane β-lactamase inhibitor, can protect meropenem from hydrolysis of KPC and OXA-48 carbapenemases. This study aims to characterise the genome of a carbapenem-resistant Klebsiella pneumoniae clinical strain with a ...
Hongxia Wen, Yu Feng, Zhiyong Zong
doaj   +2 more sources

Pharmacokinetics of sulbactam-durlobactam in patients with <i>Acinetobacter baumannii</i> ventriculitis: a report of two cases. [PDF]

Antimicrob Agents Chemother
ABSTRACT Two adult patients with ventriculitis due to Acinetobacter baumannii were treated with intravenous sulbactam-durlobactam as a part of a combination regimen. Penetration into the central nervous system was estimated (by
Pouya N, Finch NA, Granillo A, Bhimraj A, Tam VH, Miller WR.   +5 more
europepmc   +4 more sources

An overview of sulbactam‐durlobactam approval and implications in advancing therapeutics for hospital‐acquired and ventilator‐associated pneumonia by acinetobacter baumannii‐calcoaceticus complex: A narrative review

Health Science Reports
Purpose Infections caused by Acinetobacter baumannii, particularly those resistant to antibiotics such as carbapenem, have become a global health crisis with a significant mortality rate.
Ayush Anand, Amogh Verma, Sarabjeet Kaur, Priyangi Kathayat, Rachel M. Manoj, Aakanksha Aakanksha, Justice K. Turzin, Prakasini Satapathy, Mahalaqua N. Khatib, Shilpa Gaidhane, Quazi S. Zahiruddin, Neelima Kukreti, Sarvesh Rustagi, Arihant Surana   +13 more
doaj   +2 more sources